Mary Kay Ladone Sells 3,908 Shares of Kestra Medical Technologies (NASDAQ:KMTS) Stock

Posted by Brian Himes on Sep 12th, 2026

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS – Get Free Report) Director Mary Ladone sold 3,908 shares of the company’s stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $25.20, for a total value of $98,481.60. Following the transaction, the director directly owned 37,507 shares in the company, valued at $945,176.40. The trade was a 9.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kestra Medical Technologies Stock Down 3.1%

Shares of Kestra Medical Technologies stock opened at $22.85 on Friday. Kestra Medical Technologies, Ltd. has a 1 year low of $17.34 and a 1 year high of $30.00. The company has a market cap of $1.34 billion, a P/E ratio of -9.44 and a beta of 0.62. The company has a current ratio of 4.41, a quick ratio of 4.41 and a debt-to-equity ratio of 0.16. The stock has a 50-day moving average price of $25.34 and a 200 day moving average price of $22.71.

Kestra Medical Technologies (NASDAQ:KMTS – Get Free Report) last released its earnings results on Tuesday, July 14th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.08). The business had revenue of $28.64 million for the quarter. Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. As a group, analysts expect that Kestra Medical Technologies, Ltd. will post -2.29 EPS for the current fiscal year.

Kestra Medical Technologies News Roundup

Here are the key news stories impacting Kestra Medical Technologies this week:

Positive Sentiment: Kestra appointed Daniel Finney as Vice President of Research & Development and added him to its executive leadership team. Finney has more than 20 years of Class III medical-device experience and previously led Kestra’s new product development. He will oversee innovation for the Cardiac Recovery System, including strategic partnerships and artificial-intelligence initiatives, providing leadership continuity after the retirement of Phillip Foshee. Kestra Names Daniel Finney Vice President of Research & Development
Neutral Sentiment: Reported short interest was zero shares as of September 10, unchanged from the prior reporting period. This suggests limited measurable short-selling pressure, but also provides little new information for investors.
Neutral Sentiment: Analyst expectations remain mixed. BTIG maintains a $32 price target and JPMorgan has a $30 target, while other analysts are more cautious; the reported median target from recent forecasts is $24.50. The upcoming earnings release could prompt additional estimate changes. Kestra earnings preview
Negative Sentiment: Four directors sold a combined 16,424 shares worth approximately $414,000. The transactions reduced their individual holdings by about 9% to 48%. Because the sales were made to cover tax withholding on vested equity awards, they are less concerning than discretionary selling, though the cluster may weigh on sentiment. SEC insider transaction filings
Negative Sentiment: Kestra is expected to report a first-quarter loss, adding to concerns about profitability. Its latest reported quarter showed a $0.67 per-share loss, worse than the $0.59 consensus estimate, despite revenue of $28.64 million. Analysts currently forecast a full-year loss of approximately $2.29 per share.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on KMTS shares. Wolfe Research set a $30.00 target price on shares of Kestra Medical Technologies in a research report on Wednesday, July 15th. Weiss Ratings cut shares of Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, August 31st. JPMorgan Chase & Co. assumed coverage on shares of Kestra Medical Technologies in a research note on Monday, August 10th. They issued an “overweight” rating and a $30.00 price target on the stock. BTIG Research reissued a “buy” rating and set a $32.00 price objective on shares of Kestra Medical Technologies in a research report on Wednesday, September 2nd. Finally, Oppenheimer initiated coverage on Kestra Medical Technologies in a research note on Tuesday, July 21st. They issued a “market perform” rating on the stock. Four research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $28.14.

Get Our Latest Research Report on KMTS

Institutional Investors Weigh In On Kestra Medical Technologies

Several institutional investors and hedge funds have recently modified their holdings of KMTS. Corient Private Wealth LP boosted its holdings in Kestra Medical Technologies by 284.2% in the second quarter. Corient Private Wealth LP now owns 60,614 shares of the company’s stock worth $1,542,000 after purchasing an additional 44,839 shares in the last quarter. California State Teachers Retirement System raised its holdings in Kestra Medical Technologies by 2,366.0% during the second quarter. California State Teachers Retirement System now owns 686,422 shares of the company’s stock valued at $17,463,000 after buying an additional 658,587 shares in the last quarter. The Manufacturers Life Insurance Company lifted its position in shares of Kestra Medical Technologies by 6.6% in the first quarter. The Manufacturers Life Insurance Company now owns 92,515 shares of the company’s stock worth $1,844,000 after buying an additional 5,731 shares during the last quarter. Quantinno Capital Management LP bought a new stake in shares of Kestra Medical Technologies during the 1st quarter worth about $431,000. Finally, Sei Investments Co. boosted its stake in shares of Kestra Medical Technologies by 22.6% during the 1st quarter. Sei Investments Co. now owns 237,116 shares of the company’s stock worth $4,726,000 after acquiring an additional 43,753 shares in the last quarter.

About Kestra Medical Technologies

(Get Free Report)

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.